Trials / Terminated
TerminatedNCT00333476
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
A Phase 2, Randomized, Open Label, Safety, and Pharmacodynamic Study of Squalamine Lactate for Injection for the Treatment of Minimally Classic or Active Occult Choroidal Neovascularization Associated With Age-Related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (planned)
- Sponsor
- Genaera Corporation · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MSI-1256F (Squalamine Lactate) |
Timeline
- Start date
- 2006-05-01
- First posted
- 2006-06-05
- Last updated
- 2007-11-28
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00333476. Inclusion in this directory is not an endorsement.